We are live on
!
Find out more
State Street SPDR S&P Pharmaceuticals ETF
XPH
XPH
73 hedge funds and large institutions have $138M invested in State Street SPDR S&P Pharmaceuticals ETF in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
40% more capital invested
Capital invested by funds: $98.6M → $138M (+$39.5M)
12.5% more ownership
Funds ownership: 50.1% → 62.6% (+12%)
12% more funds holding
Funds holding: 65 → 73 (+8)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
36% less call options, than puts
Call options by funds: $649K | Put options by funds: $1.01M
Holders
73
Holders Change
+8
Holders Change %
+12.31%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
16
Reduced
18
Closed
11
Calls
$649K
Puts
$1.01M
Net Calls
-$358K
Net Calls Change
+$934K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$17.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$15M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$2.86M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.95M |
| 5 |
TCA
Taconic Capital Advisors
New York
|
+$1.52M |
